News | February 05, 2026
AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Topiramate is indicated as a treatment of epilepsy and migraine
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Around 7% of the Indian population suffers from IBS
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Subscribe To Our Newsletter & Stay Updated
